Intralesional Injection of Levofloxacin for the Management of Cutaneous Leishmaniasis

Launched by HAYDER ADNAN FAWZI · Jan 27, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for cutaneous leishmaniasis, which is a skin infection caused by parasites. Researchers want to see if injecting a solution called levofloxacin directly into the infected skin lesions can help heal them. The trial is open to adults aged 20 to 75 who have one or more lesions, but not more than seven. If you have recently been treated for leishmaniasis or are on certain medications, you may not be eligible to participate.

If you join this trial, you will receive weekly injections of levofloxacin into each lesion for up to six weeks, but treatment may stop earlier if your lesions heal before that time. The goal is to track how well this treatment works over a 90-day period. This study is currently recruiting participants, and it aims to provide more options for people dealing with this skin condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with single or multiple (less than seven lesions) lesions of cutaneous leishmaniasis and patients ranging in age from 20 to 75 years old.
• Exclusion Criteria:
• • Patients who received anti-leishmaniasis treatment locally or systemically for the last month before this study and patients on prolonged corticosteroid therapy.